CD274 and lymphoma: Characterization of PD-L1+ cells in these lymphomas may contribute to the development of effective approaches to the delivery anti-PD-L1 antibodies to tumors in PD-L1 blockade therapy for patients suffering from PD-L1-expressing tumors.